An AACR Special Conference
Addressing Critical Questions in Ovarian Cancer Research and Treatment

October 1-4, 2017
Wyndham Grand Pittsburgh Downtown
Pittsburgh, Pennsylvania

Sunday, October 1

Welcome Remarks and Opening Keynote Lecture
6:15 p.m.–7:30 p.m.

Welcome Remarks
Title to be announced
Joan S. Brugge, Harvard Medical School, Boston, Massachusetts

Opening Reception
7:30 p.m.–9:30 p.m.

Monday, October 2

Continental Breakfast / Networking Roundtables
7:00 a.m.–8:00 a.m.

Plenary Session 1: DNA Damage and Repair
8:00 a.m.–10:00 a.m.

**PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead?**
Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts

**Inhibition of ATR overcomes the PARP inhibitor resistance of BRCA-deficient cancer cell**
Lee Zou, MGH Cancer Center/Harvard Medical School, Boston, Massachusetts

**Mitotic progression connects DNA damage to activation of anti-tumor immune responses**
Roger A. Greenberg, University of Pennsylvania, Philadelphia, Pennsylvania

**Cyclin E: Targeting cell cycle dependencies in CCNE1 amplified tumors**
Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania

**Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition**
Monicka Wielgos-Bonvallet, NYU Langone Medical Center, New York, New York

Break
10:00 a.m.–10:30 a.m.

Plenary Session 2: Metabolic Changes in Ovarian Cancer
10:30 a.m.–12:30 p.m.

Title to be announced
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, Texas

*Short talk from proffered abstract
Stromal regulation of metastasis
Ernst R. Lengyel, University of Chicago, Chicago, Illinois

Targeting micrometastasis for the treatment of ovarian cancer

Kinase-mediated modulation of paclitaxel sensitivity in ovarian cancer
Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma*
Jennifer Xiao Ye Ji, University of British Columbia, Vancouver, BC, Canada

Free Time (Lunch on Own)
12:30 p.m.–3:00 p.m.

Plenary Session 3: Tumor Microenvironment
3:00 p.m.–5:00 p.m.

New directions in tumor microenvironment
Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas

Deconstructing and reconstructing the ovarian cancer microenvironment
Frances R. Balkwill, Barts Cancer Institute, London, England

Translating preclinical observations into trials addressing changes in the tumor microenvironment
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas

Tumor-derived indoleamine 2,3-dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid derived suppressor cells in a murine model of ovarian cancer *
Adaobi E. Amobi, Roswell Park Cancer Institute, Buffalo, New York

Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis*
Mark A. Eckert, University of Chicago, Chicago, Illinois

Panel Discussion: Innovative Trial Design
5:00 p.m.–6:00 p.m.

ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs. placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)*
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas

Additional panelists to be announced

Poster Session A / Reception
6:00 p.m.–8:30 p.m.

Tuesday, October 3

Continental Breakfast / Networking Roundtables
7:00 a.m.–8:00 a.m.

*Short talk from proffered abstract
Plenary Session 4: Drug Response and Resistance to Therapy
8:00 a.m.–10:00 a.m.

Acquired chemotherapy resistance in high-grade serous ovarian cancer patients
David D. L. Bowtell, Peter MacCallum Cancer Centre, E. Melbourne, VIC, Australia

Systems approach to drug development
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas

Exploiting synthetic lethality in the treatment of gynecological cancers
Christopher Lord, Cancer Research UK London Research Institute, London, England

Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer*
Claudia Iavarone, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts

Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer*
Kaiyang Zhang, University of Helsinki, Helsinki, Finland

Break
10:00 a.m.–10:30 a.m.

Plenary Session 5: Prevention and Early Detection
10:30 a.m.–12:30 p.m.

Early detection of ovarian cancer: An update
Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas

Molecular testing for early detection of ovarian cancer
Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, Maryland

Physical and in silico methods for improving sensitivity of detection of ctDNA for personalized medicine in high grade serous ovarian cancer
James D. Brenton, University of Cambridge, Cambridge, England

Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq*
Kevin M. Elias, Brigham and Women's Hospital, Boston, Massachusetts

Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study*
Francesmary Modugno, University of Pittsburgh, Pittsburgh, Pennsylvania

Poster Session B / Lunch
12:30 p.m.–3:00 p.m.

Plenary Session 6: Exploiting Vulnerabilities in Rare Tumors
3:00 p.m.–5:00 p.m.

Progress and future directions in the management of low-grade serous cancer of the ovary
David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, Texas

Granulosa cell and other rare ovarian cancers: Genomic-derived diagnostics and emergent management strategies
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

Therapeutic targeting ARID1A mutation in ovarian cancer
Rugang Zhang, The Wistar Institute, Philadelphia, Pennsylvania

*Short talk from proffered abstract
Small cell carcinomas of the ovary: Strengths and weaknesses
Douglas A. Levine, New York University, New York, New York

The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma*
Darren Ennis, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom

Panel: Funding Opportunities and Advocacy Groups
5:00 p.m.–6:00 p.m.

Wednesday, October 4

Continental Breakfast / Networking Roundtables
7:00 a.m.–8:00 a.m.

Plenary Session 7: Immunotherapy
8:00 a.m.–10:00 a.m.

Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, New York

How does the immune system contend with intratumoral heterogeneity in ovarian cancer?
Brad Nelson, BC Cancer Agency, Vancouver Island, BC, Canada

Translating fundamental immunobiology into adoptive T cell therapy for ovarian cancer
Daniel J. Powell, University of Pennsylvania, Philadelphia, Pennsylvania

Strategies for glycosylation-based immunotargeting of MUC16
David R. Spriggs, Memorial Sloan Kettering Cancer Center, New York, New York

Epigenetic reprogramming promotes an immunogenic ovarian tumor microenvironment and synergizes with adoptive transfer of engineered T cells expressing NY-ESO-1 specific T cell receptors*
Li Shen, Roswell Park Cancer Institute, Buffalo, New York

Break
10:00 a.m.–10:15 a.m.

Plenary Session 8: Genetics and Molecular Drivers
10:15 a.m.–12:15 p.m.

Replication road blocks in Cyclin E-amplified ovarian cancers
Ronny I. Drapkin, University of Pennsylvania, Philadelphia, Pennsylvania

Functional genetic architecture of serous ovarian cancer
Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada

Title to be announced
Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, Texas

TERT is frequently mutated in adult-type granulosa cell tumours of the ovary compared to other malignant sex cord-stromal tumors*
Jessica A. Pilsworth, University of British Columbia, Vancouver, BC, Canada

*Short talk from proffered abstract
CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high grade serous carcinoma*
Josephine Walton, The University of Glasgow, Glasgow, United Kingdom

Departure
12:15 p.m.

*Short talk from proffered abstract